Protalix BioTherapeutics Announces Positive 12-Month Interim Data From BRIDGE Phase III Open Label Switch-Over Study Showing Pegunigalsidase Alfa For The Treatment Of Fabry Disease Was Well Tolerated
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.